848PD - Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study
M. Galsky

849PD - Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)
S. Pal

850PD - Epithelial-mesenchymal transition (EMT), T cell infiltration, and outcomes with nivolumab (nivo) in urothelial cancer (UC)
M. Galsky

Invited Discussant 848PD, 849PD and 850PD
P. Grivas

Q&A led by Discussant

851PD - Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)
D. Petrylak

852PD - Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
A. Necchi

LBA37_PR - Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial
R. De Wit

Invited Discussant 851PD, 852PD and LBA37
M. De Santis

Q&A led by Discussant

LBA38 - Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
T. Choueiri

LBA39 - IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab (atezo) With or Without Bevacizumab (bev) vs Sunitinib (sun) in Untreated Metastatic Renal Cell Carcinoma (mRCC)
T. Powles

854PD - Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)
D. Bossé

855PD - Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
M. Staehler

Invited Discussant LBA38, LBA39, 854PD and 855PD
C. Porta

Q&A led by Discussant